Mid Cap Stocks To Follow Today – February 25th

ProShares UltraPro Short QQQ, CAVA Group, Arcellx, Whirlpool, and ImmunityBio are the five Mid Cap stocks to watch today, according to MarketBeat’s stock screener tool. Mid-cap stocks are shares of companies with medium market capitalizations—commonly defined as roughly $2 billion to $10 billion—positioned between large-cap and small-cap firms. They typically offer a balance of growth potential and relative stability, attracting investors seeking moderate risk and long-term capital appreciation. Exact market-cap cutoffs vary by index provider and market. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

CAVA Group (CAVA)

Arcellx (ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Whirlpool (WHR)

Whirlpool Corporation manufactures and markets home appliances and related products and services in the North America, Europe, the Middle East, Africa, Latin America, and Asia. The company's principal products include refrigerators, freezers, ice makers, and refrigerator water filters; laundry appliances, and commercial laundry products and related laundry accessories; cooking and other small domestic appliances; and dishwasher appliances and related accessories, as well as mixers.

ImmunityBio (IBRX)

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.